MX2019003544A - Composiciones que comprenden un ligando de union al receptor cannabinoide. - Google Patents

Composiciones que comprenden un ligando de union al receptor cannabinoide.

Info

Publication number
MX2019003544A
MX2019003544A MX2019003544A MX2019003544A MX2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A
Authority
MX
Mexico
Prior art keywords
receptor binding
binding ligand
cannabinoid receptor
compositions
medicament
Prior art date
Application number
MX2019003544A
Other languages
English (en)
Spanish (es)
Inventor
Günther Bernhard
Löscher Frank
Krösser Sonja
Steven Philipp
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2019003544A publication Critical patent/MX2019003544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2019003544A 2016-09-28 2017-09-27 Composiciones que comprenden un ligando de union al receptor cannabinoide. MX2019003544A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191194 2016-09-28
EP17168172 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (1)

Publication Number Publication Date
MX2019003544A true MX2019003544A (es) 2019-09-19

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003544A MX2019003544A (es) 2016-09-28 2017-09-27 Composiciones que comprenden un ligando de union al receptor cannabinoide.

Country Status (10)

Country Link
US (1) US20190343793A1 (https=)
EP (2) EP3518921B1 (https=)
JP (1) JP2019534867A (https=)
KR (1) KR20190060787A (https=)
CN (1) CN109803650A (https=)
AU (1) AU2017333420A1 (https=)
BR (1) BR112019006194A2 (https=)
CA (1) CA3036313A1 (https=)
MX (1) MX2019003544A (https=)
WO (1) WO2018060282A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
DK3181119T3 (da) 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
MX2018003781A (es) 2015-09-30 2018-09-12 Novaliq Gmbh Compuestos semifluorados para administracion oftalmica.
EP3452150B1 (en) 2016-05-03 2024-01-17 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US10732712B2 (en) * 2016-12-27 2020-08-04 Facebook Technologies, Llc Large scale integration of haptic devices
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111526914A (zh) 2017-10-04 2020-08-11 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (ko) 2018-03-28 2025-11-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
JP7665519B2 (ja) * 2019-02-01 2025-04-21 アルコン インコーポレイティド 近視を治療するための化合物、組成物及び医薬組成物
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
US12419933B2 (en) 2019-09-06 2025-09-23 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
MX2022014459A (es) 2020-05-18 2023-02-27 Max Biology Co Ltd Composiciones de lipidos y polimeros y metodos de uso.
EP4203716A1 (en) * 2020-09-24 2023-07-05 Nicoventures Trading Limited Formulation
CA3194409A1 (en) * 2020-10-05 2022-04-14 Sunil Shah Cannabinoid-containing compositions and use for treating and preventing diseases
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
JP7749020B2 (ja) 2021-02-03 2025-10-03 エーディーエス・セラピューティクス・エルエルシー 局所眼科用組成物
US11793945B2 (en) 2021-06-22 2023-10-24 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
US20250228876A1 (en) * 2021-10-13 2025-07-17 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
CN119768202A (zh) 2022-07-18 2025-04-04 精呼吸股份有限公司 小步长高分辨率气溶胶生成系统及方法
WO2026037894A1 (en) * 2024-08-15 2026-02-19 Dermaliq Therapeutics, Inc. Semifluorinated alkane compositions for cleaning the skin
WO2026047389A1 (en) * 2024-08-30 2026-03-05 Vicadia Lda Topical delivery of cannabinoid-based formulations for ocular allergy and inflammation in ophthalmic diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
WO2008019146A2 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
CN113679697A (zh) * 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
DK3181119T3 (da) * 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
US9265809B2 (en) 2013-10-09 2016-02-23 Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CA2931039C (en) * 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Also Published As

Publication number Publication date
BR112019006194A2 (pt) 2019-06-18
EP3698785A1 (en) 2020-08-26
AU2017333420A1 (en) 2019-04-04
KR20190060787A (ko) 2019-06-03
US20190343793A1 (en) 2019-11-14
WO2018060282A1 (en) 2018-04-05
EP3518921A1 (en) 2019-08-07
JP2019534867A (ja) 2019-12-05
EP3518921B1 (en) 2021-08-11
CN109803650A (zh) 2019-05-24
CA3036313A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
MX2019003544A (es) Composiciones que comprenden un ligando de union al receptor cannabinoide.
IL287128B1 (en) GLP-1R agonists, pharmaceutical compositions containing them and their uses in the treatment of cardiometabolic and related diseases
MX2022010168A (es) Moduladores de calpainas y usos terapeuticos de los mismos.
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
MX2018005340A (es) Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos.
IL276888A (en) Pharmaceutical compositions containing timolol
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MY195244A (en) Muscarinic Agonists
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
MX2016014515A (es) Composicion topica de crema gel.
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
PH12019502692A1 (en) Anti-cancer combination therapy
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
MX2018015125A (es) Nuevos compuestos antibacterianos.
PH12015502523A1 (en) Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EP4331622A3 (en) Integrin binding peptides and uses thereof
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
WO2020123753A3 (en) Anellosomes for delivering intracellular therapeutic modalities
AU2018279184A1 (en) Anti-TrkB antibodies
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
IL277649A (en) Preparations for the treatment of cancer by combining active substances
MX2024003785A (es) Inhibidor de inmunosupresion asociado al cancer.
EP3875091A4 (en) Pharmaceutical composition containing antitumor agent